278597-28-7

Basic information

• Product Name: 3-(2,6-DICHLORO-PHENYL)-5-ISOPROPYL-ISOXAZOLE-4-CARBOXYLIC ACID METHYL ESTER
• Synonyms: 3-(2,6-DICHLORO-PHENYL)-5-ISOPROPYL-ISOXAZOLE-4-CARBOXYLIC ACID METHYL ESTER;3-(2,6-Dichlorophenyl)-4-carboMethoxy-5-isopropyl-isoxazole;Methyl 3-(2,6-dichlorophenyl)-5-isopropylisoxazole-4-carboxylate;4-Isoxazolecarboxylic acid, 3-(2,6-dichlorophenyl)-5-(1-Methylethyl)-, Methyl ester;Methyl 3-(2,6-dichlorophenyl)-5-
• CAS NO: 278597-28-7
• Molecular Formula: C₁₄H₁₃Cl₂NO₃
• Molecular Weight: 314.16
• Mol File: 278597-28-7.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 427.9 °C at 760 mmHg
• Flash Point: 212.6 °C
• Appearance: /
• Density: 1.295 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.547
• Storage Temp.: 2-8°C
• PKA: -6.07±0.50(Predicted)
• CAS DataBase Reference: 3-(2,6-DICHLORO-PHENYL)-5-ISOPROPYL-ISOXAZOLE-4-CARBOXYLIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2,6-DICHLORO-PHENYL)-5-ISOPROPYL-ISOXAZOLE-4-CARBOXYLIC ACID METHYL ESTER(278597-28-7)
• EPA Substance Registry System: 3-(2,6-DICHLORO-PHENYL)-5-ISOPROPYL-ISOXAZOLE-4-CARBOXYLIC ACID METHYL ESTER(278597-28-7)

Safety Data

• Hazardous Substances Data: 278597-28-7(Hazardous Substances Data)

Usage

General Description

3-(2,6-Dichloro-phenyl)-5-isopropyl-isoxazole-4-carboxylic acid methyl ester is a chemical compound with the molecular formula C14H13Cl2NO3. It is a methyl ester derivative of isoxazole-4-carboxylic acid and contains a isopropyl and 2,6-dichloro-phenyl substituents. 3-(2,6-DICHLORO-PHENYL)-5-ISOPROPYL-ISOXAZOLE-4-CARBOXYLIC ACID METHYL ESTER is commonly used in the pharmaceutical industry as a building block for the synthesis of various drugs and biologically active molecules. It has also been studied for its potential therapeutic properties, including its anti-inflammatory and analgesic effects. Additionally, it has been investigated for its potential application in the field of agricultural chemistry, as a potential agrochemical or pesticide.

InChI:InChI=1/C14H13Cl2NO3/c1-7(2)13-11(14(18)19-3)12(17-20-13)10-8(15)5-4-6-9(10)16/h4-7H,1-3H3

Upstream product

• 25185-95-9 2,6-dichlorobenzaldoxime 
• 42558-54-3 Methyl 4-methyl-3-oxopentanoate 
• 6579-27-7 2,6-Dichloro-N-hydroxybenzenecarboximidoyl chloride 
• 6575-28-6 (1E)-2,6-dichlorobenzaldehyde oxime 
• 6579-27-7 2,6-dichlorobenzohydroximoyl chloride 
• 83-38-5 2,6-dichlorobenzaldehyde 

Downstream Products

• 1020570-56-2 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carbaldehyde 
• 700835-81-0 4-(chloromethyl)-3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole 
• 1573119-81-9 4-{[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-isopropyl-isoxazol-4-yl]methoxy]benzoyl]amino}benzoic acid 
• 1374961-91-7 methyl 4-{[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-isopropyl-isoxazol-4-yl]methoxy]benzoyl]amino}benzoate 
• 933799-64-5 2-chloro-4-{[5-isopropyl-3-(2,6-dichlorophenyl)-isoxazol-4-yl]methoxy}benzoic acid 
• 1573119-83-1 methyl 2-chloro-4-[[3-(2,6-dichlorophenyl)-5-isopropyl-isoxazol-4-yl]methoxy]benzoate 
• 1573119-79-5 3-(2,6-dichlorophenyl)-4-(4'-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole 
• 1573119-78-4 3-(2,6-dichlorophenyl)-4-(2'-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole 
• 1573119-80-8 3-(2,6-dichlorophenyl)-4-(4'-methoxycarbonyl-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole 
• 1573119-82-0 3-(2,6-dichlorophenyl)-4-(2'-methoxycarbonyl-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole 
• 774605-58-2 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carboxylic acid 
• 933799-50-9 3-(2,6-dichlorophenyl)-4-(3'-carbomethoxy-2-chloro-stilben-4-yl)-oxymethyl-5-isopropyl-isoxazole 
• 1089660-72-9 (E)-3-(2-chloro-4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)styryl)benzoic acid 
• 278597-32-3 3-(2,6-dichlorophenyl)-4-(3'-chloro-4'-formylphenoxy)-methyl-5-isopropyl-isoxazole 

Relevant articles and documents

Optical control of the nuclear bile acid receptor FXR with a photohormone

Herein, we report a photoswitchable modulator for a nuclear hormone receptor that exerts its hormonal effects in a light-dependent fashion. The azobenzene AzoGW enables optical control of the farnesoid X receptor (FXR), a key regulator of hepatic bile aci

Design and Structural Optimization of Dual FXR/PPARδActivators

Nonalcoholic steatohepatitis (NASH) is considered as severe hepatic manifestation of the metabolic syndrome and has alarming global prevalence. The ligand-activated transcription factors farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) δhave been validated as molecular targets to counter NASH. To achieve robust therapeutic efficacy in this multifactorial pathology, combined peripheral PPAR?-mediated activity and hepatic effects of FXR activation appear as a promising multitarget approach. We have designed a minimal dual FXR/PPARδactivator scaffold by rational fusion of pharmacophores derived from selective agonists. Our dual agonist lead compound exhibited weak agonism on FXR and PPARδand was structurally refined to a potent and balanced FXR/PPARδactivator in a computer-aided fashion. The resulting dual FXR/PPARδmodulator comprises high selectivity over related nuclear receptors and activates the two target transcription factors in native cellular settings.

Structure-guided design and synthesis of isoflavone analogs of GW4064 with potent lipid accumulation inhibitory activities

Our group has previously reported a series of isoflavone derivatives with antidyslipidemic activity. With this background, a series of isoflavone analogs of GW4064 were designed, synthesized and evaluated the lipid-lowering activity of analogs. As a result, most of compounds significantly reduced the lipid accumulation in 3T3-L1 adipocytes and four of them (10a, 11, 15c and 15d) showed stronger inhibitory than GW4064. The most potent compound 15d exhibited promising agonistic activity for FXR in a cell-based luciferase reporter assay. Meanwhile, 15d up-regulated FXR, SHP and BSEP gene expression and down-regulated the mRNA expression of lipogenesis gene SREBP-1c. Besides, an improved safety profile of 15d was also observed in a HepG2 cytotoxicity assay compared with GW4064. The obtained biological results were further confirmed by a molecular docking study showing that 15d fitted well in the binding pocket of FXR and interacted with some key residues simultaneously.